Invariant natural killer T (iNKT) cells produce copious amounts of cytokines in response to specific glycolipid antigens such as α-galactosylceramide (αGalCer) presented by CD1d-expressing antigen-presenting cells (APCs), thus orchestrating other immune cells to fight tumors. Because of their...
Macrophages and dendritic cells lacking the transcription factor nuclear factor kappa B p50 are skewed toward a proinflammatory phenotype, with increased cytokine expression and enhanced T cell activation; additionally, murine melanoma, fibrosarcoma, colon carcinoma, and glioblastoma grow slower...
Dendritic cell (DC) vaccine efficacy is directly related to the efficiency of DC migration to the lymph node after delivery to the patient. The authors discovered that a naturally occurring metabolite, sarcosine, increases DC migration in human and murine cells resulting in significantly...
TNF receptor family agonists and checkpoint blockade combination therapies lead to minimal tumor clearance of poorly immunogenic tumors. Therefore, a need to enhance the efficacy of this combination therapy arises. Antigen-presenting cells (APCs) present antigen to T cells and steer the immune...
The tumor microenvironment exists in a state of dynamic equilibrium, in which a balance of agonist and antagonist signals govern the anti-tumor immune responses. Previous studies have shown that chemotherapy could shift this balance in favor of agonistic signals for the anti-tumor immune...
Dendritic cells (DCs) are central players in the immune system, with an exquisite capacity to initiate and modulate immune responses. These functional characteristics have led to intense research on the development of DC-based immunotherapies, particularly for oncologic diseases. During recent...
Despite major advancements in immunotherapy among a number of solid tumors, response rates among ovarian cancer patients remain modest. Standard treatment for ovarian cancer is still surgery followed by taxane- and platinum-based chemotherapy. Thus, there is an urgent need to develop novel...
For decades, doctors and researchers have conducted clinical trials to further progress in the clinical implementation of tumor immunotherapy. Former President Jimmy Carter's success with immunotherapy for advanced melanoma and Vice President Joe Biden's Cancer Moonshot Initiative have brought...
ImmunotherapyforMelanomaProfessionaledition.pdf
The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer. This open access, peer-reviewed journal publishes original research articles, literature reviews, position papers and more on all aspects of tumor immunology and cancer...
Immunotherapy is the newest type of treatment available for people with cancer. For decades, doctors and researchers have conducted clinical trials to further the progress in immunotherapy as cancer treatment. Former President Jimmy Carter's success with immunotherapy for advanced melanoma and...
ImmunotherapyforMelanomaPatientedition.pdf
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us